Scuola di Scienze del Farmaco e dei Prodotti della Salute, Università di Camerino, Camerino (MC), Italy.
Malar J. 2010 Mar 2;9:66. doi: 10.1186/1475-2875-9-66.
The wide use of gametocytocidal artemisinin-based combination therapy (ACT) lead to a reduction of Plasmodium falciparum transmission in several African endemic settings. An increased impact on malaria burden may be achieved through the development of improved transmission-blocking formulations, including molecules complementing the gametocytocidal effects of artemisinin derivatives and/or acting on Plasmodium stages developing in the vector. Azadirachtin, a limonoid (tetranortriterpenoid) abundant in neem (Azadirachta indica, Meliaceae) seeds, is a promising candidate, inhibiting Plasmodium exflagellation in vitro at low concentrations. This work aimed at assessing the transmission-blocking potential of NeemAzal(R), an azadirachtin-enriched extract of neem seeds, using the rodent malaria in vivo model Plasmodium berghei/Anopheles stephensi.
Anopheles stephensi females were offered a blood-meal on P. berghei infected, gametocytaemic BALB/c mice, treated intraperitoneally with NeemAzal, one hour before feeding. The transmission-blocking activity of the product was evaluated by assessing oocyst prevalence, oocyst density and capacity to infect healthy mice. To characterize the anti-plasmodial effects of NeemAzal(R) on early midgut stages, i.e. zygotes and ookinetes, Giemsa-stained mosquito midgut smears were examined.
NeemAzal completely blocked P. berghei development in the vector, at an azadirachtin dose of 50 mg/kg mouse body weight. The totally 138 examined, treated mosquitoes (three experimental replications) did not reveal any oocyst and none of the healthy mice exposed to their bites developed parasitaemia. The examination of midgut content smears revealed a reduced number of zygotes and post-zygotic forms and the absence of mature ookinetes in treated mosquitoes. Post-zygotic forms showed several morphological alterations, compatible with the hypothesis of an azadirachtin interference with the functionality of the microtubule organizing centres and with the assembly of cytoskeletal microtubules, which are both fundamental processes in Plasmodium gametogenesis and ookinete formation.
This work demonstrated in vivo transmission blocking activity of an azadirachtin-enriched neem seed extract at an azadirachtin dose compatible with 'druggability' requisites. These results and evidence of anti-plasmodial activity of neem products accumulated over the last years encourage to convey neem compounds into the drug discovery & development pipeline and to evaluate their potential for the design of novel or improved transmission-blocking remedies.
在几个非洲流行地区,广泛使用配子体杀伤型青蒿素复方疗法(ACT)导致恶性疟原虫传播减少。通过开发改良的传播阻断配方,包括补充青蒿素衍生物配子体杀伤作用的分子和/或作用于蚊媒中发育的疟原虫阶段,可能会对疟疾负担产生更大的影响。印楝素是一种存在于印楝(Azadirachta indica,楝科)种子中的柠檬苦素(四萜类化合物),是一种很有前途的候选药物,在低浓度下即可抑制疟原虫的出芽。本研究旨在使用体内疟原虫模型伯氏疟原虫/按蚊,评估 NeemAzal(一种富含印楝素的印楝种子提取物)的传播阻断潜力。
用感染伯氏疟原虫的、配子体血症的 BALB/c 小鼠经腹腔注射 NeemAzal 进行预处理,1 小时后给感染疟原虫的按蚊雌性喂食。通过评估卵囊发生率、卵囊密度和感染健康小鼠的能力来评估产品的传播阻断活性。为了表征 NeemAzal(R)对早期中肠阶段(即合子和卵囊)的抗疟原虫作用,用吉姆萨染色的蚊子中肠涂片进行检查。
以 50mg/kg 小鼠体重的印楝素剂量,NeemAzal 完全阻断了疟原虫在蚊媒中的发育。在 138 只接受检查的蚊子(三个实验重复)中,没有发现任何卵囊,也没有一只暴露于它们叮咬的健康小鼠发生寄生虫血症。中肠内容物涂片检查显示,处理过的蚊子中合子和合子后阶段的数量减少,成熟卵囊虫也不存在。合子后阶段出现了几种形态改变,这与印楝素干扰微管组织中心的功能和细胞骨架微管组装的假说一致,而这两个过程都是疟原虫配子发生和卵囊形成的基本过程。
本研究在体内证实了富含印楝素的印楝种子提取物在与“可成药性”要求相符的印楝素剂量下具有传播阻断活性。这些结果和过去几年积累的印楝产品抗疟原虫活性的证据,鼓励将印楝化合物纳入药物发现和开发管道,并评估它们在设计新型或改良的传播阻断药物方面的潜力。